Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Compass Therapeutics (CMPX) Gains from Sales and Divestitures: 2023-2025

Historic Gains from Sales and Divestitures for Compass Therapeutics (CMPX) over the last 3 years, with Sep 2025 value amounting to $823,000.

  • Compass Therapeutics' Gains from Sales and Divestitures rose 265.78% to $823,000 in Q3 2025 from the same period last year, while for Sep 2025 it was $823,000, marking a year-over-year increase of 265.78%. This contributed to the annual value of $525,000 for FY2024, which is 75.00% up from last year.
  • Compass Therapeutics' Gains from Sales and Divestitures amounted to $823,000 in Q3 2025, which was down 0.00% from $823,000 recorded in Q2 2025.
  • Compass Therapeutics' 5-year Gains from Sales and Divestitures high stood at $823,000 for Q1 2025, and its period low was $122,000 during Q2 2023.
  • Its 3-year average for Gains from Sales and Divestitures is $425,300, with a median of $262,500 in 2023.
  • Data for Compass Therapeutics' Gains from Sales and Divestitures shows a peak YoY soared of 265.78% (in 2025) over the last 5 years.
  • Over the past 3 years, Compass Therapeutics' Gains from Sales and Divestitures (Quarterly) stood at $300,000 in 2023, then spiked by 75.00% to $525,000 in 2024, then spiked by 265.78% to $823,000 in 2025.
  • Its Gains from Sales and Divestitures stands at $823,000 for Q3 2025, versus $823,000 for Q2 2025 and $823,000 for Q1 2025.